Cargando…

PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms

Background: Lower urinary tract symptoms (LUTS) affect more than half of men over age 70 and contribute to both poor health-related quality of life and polypharmacy. Tamsulosin hydrochloride, a selective α(1)-blocker, is the most common medication used to treat LUTS due to presumed benign prostatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Scott R., Breyer, Benjamin N., Oni-Orisan, Akinyemi, Steinman, Michael A., Sim, Ida, McCulloch, Charles E., Kenfield, Stacey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521798/
https://www.ncbi.nlm.nih.gov/pubmed/34713020
http://dx.doi.org/10.3389/fdgth.2020.00007
_version_ 1784584960004325376
author Bauer, Scott R.
Breyer, Benjamin N.
Oni-Orisan, Akinyemi
Steinman, Michael A.
Sim, Ida
McCulloch, Charles E.
Kenfield, Stacey A.
author_facet Bauer, Scott R.
Breyer, Benjamin N.
Oni-Orisan, Akinyemi
Steinman, Michael A.
Sim, Ida
McCulloch, Charles E.
Kenfield, Stacey A.
author_sort Bauer, Scott R.
collection PubMed
description Background: Lower urinary tract symptoms (LUTS) affect more than half of men over age 70 and contribute to both poor health-related quality of life and polypharmacy. Tamsulosin hydrochloride, a selective α(1)-blocker, is the most common medication used to treat LUTS due to presumed benign prostatic hyperplasia and is often prescribed indefinitely, although not all men benefit from long-term therapy. N-of-1 trials allow for individualized estimates of benefit and harm and could facilitate decisions regarding chronic tamsulosin therapy for LUTS, particularly among older men. Our team developed the PERSONAL (PlacEbo-controlled, Randomized, patient-Selected Outcomes, N-of-1 triALs) app to track daily urinary symptoms and medication side effects for n-of-1 trials among older men with LUTS. Materials and Methods: We will conduct a feasibility study of 20 individual randomized n-of-1 trials using the PERSONAL app to compare tamsulosin (0.4 or 0.8 mg) vs. placebo among older men taking tamsulosin for LUTS. We will include men over age 65 with a smartphone for whom temporary discontinuation of tamsulosin is safe, (e.g., no history of acute retention). Participants will work with research staff to prospectively identify the most important urinary symptoms and medication side effects that they would like to digitally track. Men will then be randomized to 2-week treatment periods of tamsulosin or placebo followed by a 1-week wash-out with placebo, for 4 distinct treatment periods and 3 wash-out periods, totaling 11 weeks. Study medications will be blinded using over-encapsulation of tamsulosin pills and matching placebo. Our primary outcomes for this study will be recruitment and retention of eligible men, completion rates of n-of-1 trials and daily questionnaires using the PERSONAL app, and participants' perceived usefulness of their n-of-1 trial for determining whether tamsulosin is effective for them. Linear mixed effects models with individual-specific intercepts and intervention effects will also be used to estimate within-individual effects of tamsulosin. Discussion: The goal of this innovative study is to establish feasibility and acceptability of using a mobile health app and n-of-1 trials to provide older men with individualized estimates of benefits and harms of chronic tamsulosin therapy for LUTS.
format Online
Article
Text
id pubmed-8521798
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85217982021-10-27 PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms Bauer, Scott R. Breyer, Benjamin N. Oni-Orisan, Akinyemi Steinman, Michael A. Sim, Ida McCulloch, Charles E. Kenfield, Stacey A. Front Digit Health Digital Health Background: Lower urinary tract symptoms (LUTS) affect more than half of men over age 70 and contribute to both poor health-related quality of life and polypharmacy. Tamsulosin hydrochloride, a selective α(1)-blocker, is the most common medication used to treat LUTS due to presumed benign prostatic hyperplasia and is often prescribed indefinitely, although not all men benefit from long-term therapy. N-of-1 trials allow for individualized estimates of benefit and harm and could facilitate decisions regarding chronic tamsulosin therapy for LUTS, particularly among older men. Our team developed the PERSONAL (PlacEbo-controlled, Randomized, patient-Selected Outcomes, N-of-1 triALs) app to track daily urinary symptoms and medication side effects for n-of-1 trials among older men with LUTS. Materials and Methods: We will conduct a feasibility study of 20 individual randomized n-of-1 trials using the PERSONAL app to compare tamsulosin (0.4 or 0.8 mg) vs. placebo among older men taking tamsulosin for LUTS. We will include men over age 65 with a smartphone for whom temporary discontinuation of tamsulosin is safe, (e.g., no history of acute retention). Participants will work with research staff to prospectively identify the most important urinary symptoms and medication side effects that they would like to digitally track. Men will then be randomized to 2-week treatment periods of tamsulosin or placebo followed by a 1-week wash-out with placebo, for 4 distinct treatment periods and 3 wash-out periods, totaling 11 weeks. Study medications will be blinded using over-encapsulation of tamsulosin pills and matching placebo. Our primary outcomes for this study will be recruitment and retention of eligible men, completion rates of n-of-1 trials and daily questionnaires using the PERSONAL app, and participants' perceived usefulness of their n-of-1 trial for determining whether tamsulosin is effective for them. Linear mixed effects models with individual-specific intercepts and intervention effects will also be used to estimate within-individual effects of tamsulosin. Discussion: The goal of this innovative study is to establish feasibility and acceptability of using a mobile health app and n-of-1 trials to provide older men with individualized estimates of benefits and harms of chronic tamsulosin therapy for LUTS. Frontiers Media S.A. 2020-06-26 /pmc/articles/PMC8521798/ /pubmed/34713020 http://dx.doi.org/10.3389/fdgth.2020.00007 Text en Copyright © 2020 Bauer, Breyer, Oni-Orisan, Steinman, Sim, McCulloch and Kenfield. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Digital Health
Bauer, Scott R.
Breyer, Benjamin N.
Oni-Orisan, Akinyemi
Steinman, Michael A.
Sim, Ida
McCulloch, Charles E.
Kenfield, Stacey A.
PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title_full PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title_fullStr PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title_full_unstemmed PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title_short PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms
title_sort personal: feasibility study protocol for placebo-controlled, randomized n-of-1 trials of tamsulosin for lower urinary tract symptoms
topic Digital Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521798/
https://www.ncbi.nlm.nih.gov/pubmed/34713020
http://dx.doi.org/10.3389/fdgth.2020.00007
work_keys_str_mv AT bauerscottr personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT breyerbenjaminn personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT oniorisanakinyemi personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT steinmanmichaela personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT simida personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT mccullochcharlese personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms
AT kenfieldstaceya personalfeasibilitystudyprotocolforplacebocontrolledrandomizednof1trialsoftamsulosinforlowerurinarytractsymptoms